# Neurogene

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/neurogene

- Industry: Biotechnology
- Headquarters: New York, US
- Website: www.neurogene.com
- Total disclosed funding: $138M
- Latest round: Series B (Dec 16, 2020)
- Investors on record: 11

## About

Based in the US, Neurogene Inc. specializes in innovative gene therapies, focusing on addressing neurological disorders with its proprietary technologies and therapies.Founded in 2018 and headquartered in New York, Neurogene Inc. develops genetic medicines aimed at treating rare neurological diseases. The company, led by CEO Rachel McMinn, has engaged in 4 funding deals, with its latest funding round being a PIPE that raised USD 200.00 mn on November 4, 2024. This funding was sourced from various investors including Casdin Capital and EcoR1 Capital, contributing to a total raised of USD 200.00 mn.Neurogene focuses on developing innovative genetic medicines, particularly through its core product offering, the NGN-401 gene therapy candidate, which employs the proprietary EXACT™ technology. This technology is designed to regulate transgene expression, addressing the critical needs of patients with dosage-sensitive neurological disorders such as Rett syndrome. Neurogene aims to alleviate the burden of devastating neurological diseases by providing therapeutic options that have the potential to improve patient outcomes and quality of life. The primary end users of these genetic medicines are families affected by rare neurological conditions, and the company’s products are targeted towards healthcare providers and specialists in the field of genetic therapy. Neurogene has plans to expand its gene therapy pipeline, potentially reaching markets across North America and Europe, where there is a significant unmet medical need for effective treatments for rare neurological diseases.Neurogene generates revenue primarily through partnerships and collaborations within the biotechnology and pharmaceutical sectors, focusing on advancing its gene therapy programs. The business model is built around strategic alliances with research institutions and healthcare providers, facilitating clinical trials and the eventual commercialization of its gene therapy products. Transactions typically involve agreements for licensing and co-development, enabling Neurogene to capitalize on its innovative technologies while sharing development costs and risks. Pricing structures for its therapies are determined as part of these collaborations, with the flagship NGN-401 potentially entering pricing negotiations based on clinical data and therapeutic value upon regulatory approval. The revenue model is heavily reliant on successful clinical outcomes and the adoption of its therapies by medical professionals, further solidifying Neurogene’s commitment to transforming the treatment landscape for neurological diseases.In November 2024, Neurogene Inc. raised approximately USD 200.00 mn in PIPE funding, which will be utilized to complete enrollment of a future registrational study for NGN-401 for Rett syndrome, scale up CMC to support NGN-401 registrational activities, and further develop its EXACT gene therapy pipeline. Additionally, the company aims to expand into new markets, specifically targeting regions in North America and Europe by leveraging its innovative gene therapies to meet the unmet medical needs in these areas.

## Funding rounds

- Series B, Dec 16, 2020, $69M — Alexandria Venture Investments, ArrowMark Partners, BlackRock, Redmile Group, Casdin Capital, Ascendant Capital, EcoR1 Capital, Cormorant Asset Management, Janus Henderson Investors, Samsara BioCapital, Avidity Partners Management
- Series A, Feb 12, 2019, $69M — Redmile Group, EcoR1 Capital, Cormorant Asset Management, Samsara BioCapital

## Investors

- Redmile Group (https://capitalatlas.ai/funds/redmile-group) — Series A, Series B
- EcoR1 Capital (https://capitalatlas.ai/funds/ecor1-capital) — Series A, Series B
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series A, Series B
- Samsara BioCapital (https://capitalatlas.ai/funds/samsara-biocapital) — Series A, Series B
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series B
- ArrowMark Partners — Series B
- BlackRock (https://capitalatlas.ai/funds/blackrock) — Series B
- Casdin Capital (https://capitalatlas.ai/funds/casdin-capital) — Series B
- Ascendant Capital (https://capitalatlas.ai/funds/ascendant-capital) — Series B
- Janus Henderson Investors — Series B
- Avidity Partners Management — Series B